Observational Prospective Study to Evaluate AEs, Risk Factors and Drug Utilization of BUSCAPINA COMPOSITUM N in Adults From Metropolitan Lima

Acute Pain Clinical Trial

Official title:

Observational Prospective Cohort Study to Evaluate the Incidence of Adverse Events (AE), Risk Factors, and Drug Utilization Patterns Related to Treatment With BUSCAPINA COMPOSITUM N From March to December 2016 in Patients From Metropolitan Lima

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02910167
• Other study ID #: 218.705
• Status: Completed
• Start date: October 15, 2016
• Est. completion date: February 20, 2017

Study information

• Verified date: March 2019
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

What AE occur in routine clinical practice, what is the incidence of AE and Adverse Drug Reaction, how many patients present with AE symptoms related to a potential liver injury. What are the drug utilization patterns in patients, what are the predisposing factors for the occurrence of adverse events and adverse drug reactions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 360
• Est. completion date: February 20, 2017
• Est. primary completion date: February 20, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. Patients 18 years of age and older who have received at least one dose of BUSCAPINA COMPOSITUM N according to label indications and who attend to one of the pharmacies, clinics, or private doctors office selected for the study.

2. Patients who agree to adhere to the protocol procedures of this study.

3. Women who are not pregnant or breast feeding

4. Persons who sign the informed consent

Exclusion criteria:

1. Patients with allergy to BUSCAPINA COMPOSITUM N or any of the compounds in the formula.

2. Patients with mechanical stenosis of the gastrointestinal tract.

3. Patients with myasthenia gravis.

4. Patients with megacolon.

5. Patients breastfeeding at the time of enrollment or who have become pregnant during treatment with BUSCAPINA COMPOSITUM N.

6. Patients with clinical evidence of immunosuppression.

7. Patients with urinary retention subvesical obstruction (such as prostatic adenoma).

8. Patients with right-angle glaucoma.

9. Patients with tachycardia and tachyarrhythmia.

10. Patients with severe hepatic impairment.

11. Patients with psychiatric disorders.

12. Patients with alcohol dependence or drugs.

13. Patients who discontinue the protocol are not eligible for re-enrollment.

14. Researchers, company personnel or their relatives.

Related Conditions & MeSH terms

• Acute Pain
• Dysmenorrhea

Intervention

Drug:
• Hyoscine n-butylbromide
Hyoscine n-butylbromide 10 mg
• Paracetamol
Paracetamol 500 mg
• Hyoscine n-butylbromide
Hyoscine n-butylbromide 10 mg
• Paracetamol
Paracetamol 500 mg

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

Peru, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Patients With an Incidence of Adverse Event (AE) Associated to Potential Liver Damage During the Clinical Evaluation of Patients	Percentage of patients with an incidence of Adverse Event (AE) associated to potential liver damage during the clinical evaluation of patients.	From the initial dose of study drug until end of the follow up period, up to 113 days
Secondary	Percentage of Patients With Different Transaminase Levels Found by the Doctor During the Clinical Evaluation of Patients With Symptoms Related to Potential Liver Damage.	Percentage of patients with different transaminase levels found by the doctor during the clinical evaluation of patients with symptoms related to potential liver damage. No patient with symptoms related to potential liver damage was identified, thus analyses of transaminase levels was not performed.	From the initial dose of study drug until end of the follow up period, up to 113 days
Secondary	Percentage of Patients With Different Drug Utilization Patterns of Buscapina Compositum N in Patients in Metropolitan Lima	Percentage of patients with different drug utilization patterns of Buscapina Compositum N in patients in Metropolitan Lima.	From the initial dose of study drug until end of the follow up period, up to 113 days
Secondary	Percentage of Patients Per Adverse Event Preferred Term in Patients Who Developed Any Adverse Event During Treatment	Percentage of patients per adverse event preferred term in patients who developed any adverse event during treatment with Buscapina Compositum N.	From the initial dose of study drug until end of the follow up period, up to 113 days
Secondary	Percentage of Patients With Different Variables Related to the Occurrence of Increase of Transaminases in Patients Under Treatment With Buscapina Compositum N	Percentage of patients with different variables related to the occurrence of increase of transaminases in patients under treatment with Buscapina Compositum N in Metropolitan Lima. No patient with symptoms related to potential liver damage was identified, thus analyses of transaminase levels was not performed.	From the initial dose of study drug until end of the follow up period, up to 113 days

External Links

•   Link